title: A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
abstract: This open-label, randomized study compared the efficacy of a regimen of corticosteroids and tacrolimus (standard therapy group, n = 79) with a regimen of daclizumab induction therapy in combination with mycophenolate mofetil and tacrolimus (modified therapy group, n = 78) in primary liver transplant recipients. The primary endpoint was biopsy-proven acute rejection (BPAR) at 24 weeks. Secondary endpoints included time to rejection and patient and graft survival. The incidence of BPAR was significantly reduced in the modified therapy group compared to the standard therapy group (11.5% versus 26.6%, respectively, P = 0.017). The time to rejection was significantly shorter in the standard therapy group compared with the modified therapy group (P = 0.044). There was no significant difference between groups in patient or graft survival. Hepatitis C virus-positive patients exhibited no differences from hepatitis C virus-negative patients with respect to the incidence of BPAR. A steroid-sparing regimen of daclizumab, mycophenolate mofetil, and tacrolimus was effective and well tolerated in the prevention of BPAR in adult liver transplant recipients in comparison with a standard regimen of tacrolimus and steroids.
authors.affiliation: Hospital Juan Canalejo, La Coruña, Spain. sandra@canalejo.org
authors.forename: Alejandra
authors.initials: A
authors.lastname: Otero
authors.forename: Evaristo
authors.initials: E
authors.lastname: Varo
authors.forename: Jorge Ortiz
authors.initials: JO
authors.lastname: de Urbina
authors.forename: Rafael
authors.initials: R
authors.lastname: Martín-Vivaldi
authors.forename: Valentin
authors.initials: V
authors.lastname: Cuervas-Mons
authors.forename: Ignacio
authors.initials: I
authors.lastname: González-Pinto
authors.forename: Antoni
authors.initials: A
authors.lastname: Rimola
authors.forename: Angel
authors.initials: A
authors.lastname: Bernardos
authors.forename: Santiago
authors.initials: S
authors.lastname: Otero
authors.forename: Jorge
authors.initials: J
authors.lastname: Maldonado
authors.forename: Jose I
authors.initials: JI
authors.lastname: Herrero
authors.forename: Elena
authors.initials: E
authors.lastname: Barrao
authors.forename: Rosa
authors.initials: R
authors.lastname: Domínguez-Granados
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D053208:Kaplan-Meier Estimate; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D009894:Opportunistic Infections / Q000453:epidemiology; D011446:Prospective Studies; D013256:Steroids / Q000008:administration & dosage* / Q000009:adverse effects; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D013256:Steroids; D000077561:Daclizumab; D009173:Mycophenolic Acid; D016559:Tacrolimus